Atara Biotherapeutics, Inc.
ATRA
$14.10
$1.5512.35%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 117.57% | 103.20% | 93.29% | 69.07% | 54.12% |
| Total Depreciation and Amortization | -57.97% | -15.07% | 8.97% | 4.60% | 5.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -39.24% | -32.53% | -26.05% | -32.37% | -19.59% |
| Change in Net Operating Assets | -690.64% | -442.22% | -535.59% | -301.81% | -163.96% |
| Cash from Operations | 26.35% | 54.99% | 63.49% | 64.39% | 52.54% |
| Capital Expenditure | 55.00% | 81.29% | 87.49% | 79.89% | 83.55% |
| Sale of Property, Plant, and Equipment | -- | 1,296.00% | -- | -- | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -16.96% | -101.38% | -92.29% | -92.91% | -90.75% |
| Cash from Investing | -13.88% | -101.13% | -92.32% | -93.04% | -90.80% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 44.38% | 22.76% | -6.15% | 5.81% | -2.11% |
| Issuance of Common Stock | -86.52% | -99.99% | -99.21% | 208.98% | 251.90% |
| Repurchase of Common Stock | -1,450.00% | -1,450.00% | -1,228.57% | -5.32% | 93.62% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -70.79% | 246.20% | 138.91% | 390,915.38% | 101,712.00% |
| Cash from Financing | -74.19% | 101.10% | 34.63% | 2,849.35% | 86.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -122.80% | 0.19% | -55.60% | 98.79% | -1,104.07% |